Literature DB >> 20553955

Spleen tyrosine kinases: biology, therapeutic targets and drugs.

Mauro Riccaboni1, Ivana Bianchi, Paola Petrillo.   

Abstract

Spleen tyrosine kinase (Syk) is an intriguing protein tyrosine kinase involved in signal transduction in a variety of cell types, and its aberrant regulation is associated with different allergic disorders and antibody-mediated autoimmune diseases such as rheumatoid arthritis, asthma and allergic rhinitis. Syk also plays an important part in the uncontrolled growth of tumor cells, particularly B cells. For these reasons, Syk is considered one of the most interesting biological targets of the last decade, as proved by the great number of papers and patents published, and the possibility of treating these pathologies by means of Syk kinase inhibitors has led to a great interest from the pharmaceutical and biotech industry. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553955     DOI: 10.1016/j.drudis.2010.05.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  24 in total

1.  Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity.

Authors:  Simão Luz; Patthara Kongsuphol; Ana Isabel Mendes; Francisco Romeiras; Marisa Sousa; Rainer Schreiber; Paulo Matos; Peter Jordan; Anil Mehta; Margarida D Amaral; Karl Kunzelmann; Carlos M Farinha
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

2.  Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?

Authors:  José A Gómez-Puerta; Xavier Bosch
Journal:  Nat Rev Rheumatol       Date:  2011-02-08       Impact factor: 20.543

3.  Cancer genomics: from discovery science to personalized medicine.

Authors:  Lynda Chin; Jannik N Andersen; P Andrew Futreal
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

4.  Intracellular Signaling Pathways in Rheumatoid Arthritis.

Authors:  Charles J Malemud
Journal:  J Clin Cell Immunol       Date:  2013-08-19

Review 5.  Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.

Authors:  David L Scott
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

6.  The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells.

Authors:  Erola Ainsua-Enrich; Damiana Alvarez-Errico; Alasdair M Gilfillan; César Picado; Joan Sayós; Juan Rivera; Margarita Martín
Journal:  J Immunol       Date:  2012-08-15       Impact factor: 5.422

Review 7.  Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema.

Authors:  Katherine Altman; Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

8.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

9.  Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6.

Authors:  Nan-Lin Wu; Duen-Yi Huang; Hsin-Ni Tsou; Ying-Cing Lin; Wan-Wan Lin
Journal:  J Invest Dermatol       Date:  2014-09-09       Impact factor: 8.551

Review 10.  Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma.

Authors:  Yuran Xie; Olivia M Merkel
Journal:  Arch Pharm (Weinheim)       Date:  2015-07-07       Impact factor: 3.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.